(Press-News.org) A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.
The multi-centre, double-blind, randomised, phase 3 trial compared oral dabrafenib (150 mg twice daily) and oral trametinib (2 mg once daily) combination therapy with oral dabrafenib (150 mg twice daily) and placebo.
All trial patients had inoperable stage 3C or 4 metastatic melanoma that had a BRAF gene mutation V600E or V600K. Among cancer patients with metastatic melanoma, about 40 per cent have a BRAF gene mutation – an abnormality that assists some melanoma tumours to grow and spread.
Led by Associate Professor Georgina Long of Melanoma Institute Australia at the University of Sydney, the finding affirms accumulating evidence of the efficacy of targeted combination therapies in extending life and halting disease progression in patients with cancers that carry genetic mutations that resist monotherapies.
"We show a significant 25 per cent reduction in the risk of disease progression with the combination of dabrafenib and trametinib over single-agent dabrafenib," says A/Professor Long.
"We also report a significant 37 per cent relative reduction in the risk of death among people who received the combination drug therapy compared with monotherapy.
The research also reports that two in three patients (67%) treated with the combination therapy had a complete or partial response compared to one in two patients (51%) treated with monotherapy.
"This means that significantly more patients who received combination therapy experienced complete or partial tumour regression compared to patients who received monotherapy," says A/Professor Long.
"Unlike standard chemotherapy, so-called BRAF-targeted therapies are designed to interact with specific molecules that are part of the pathways and processes used by cancer cells to grow, divide, and spread in the body.
"Further, these new generation targeted drugs act on specific molecular targets in cancer cells that have been identified through research, while most standard chemotherapies act indiscriminately on all rapidly dividing cells.
"They're designed to target specific vulnerabilities in the cancer cell, while most standard chemotherapies were identified through trial and error. Also, targeted therapies tend to have fewer and less toxic side effects than standard chemotherapy, because they do less damage to normal cells."
"However, trials of BRAF-targeted monotherapies reveal that half the patients start to develop resistance about six to seven months after starting therapy. This is why researchers are conducting trials of combination therapies that target and interrupt the mechanisms that allow cancer cells to resist monotherapies.
"Our new report confirms the accumulating evidence that targeted combination therapies can extend life and halt disease progression among people with metastatic cancer who carry genetic mutations in their cancer that resist standard chemotherapy treatments and targeted monotherapies."
INFORMATION:
Melanoma Institute Australia (MIA) is currently recruiting people into nine trials assessing the efficacy of a range of new generation targeted therapies. It has a further 16 cancer treatment trials that are active and in follow up. Ten additional trials are anticipated to open in the next six months. MIA also has a large bio-specimen bank of melanoma human tissue and blood, to improve understanding of cancer treatments and inform future clinical trials.
Targeted combination therapy halts disease, extends life in advanced melanoma patients
2014-09-29
ELSE PRESS RELEASES FROM THIS DATE:
Investigating the 'underground' habitat of Listeria bacteria
2014-09-29
The literature describes Listeria as ubiquitous bacteria with widespread occurrence. Yet they only become a problem for humans and animals when they contaminate food processing facilities, multiply, and enter the food chain in high concentrations. An infection with Listeria monocytogenes can even be fatal for humans or animals with weakened immune systems.
Listeria in soil or water are not dangerous
"Listeria in soil or water represent a relatively low risk to humans," explains study director Beatrix Stessl. "The concentrations are too low. The aim of our study was ...
Trial shows trastuzumab should remain as standard of care for HER2-positive breast cancer
2014-09-29
JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.
This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than ...
Tooth serves as evidence of 220 million-year-old attack
2014-09-29
At the beginning of the age of dinosaurs, gigantic reptiles—distant relatives of modern crocodiles—ruled the earth. Some lived on land and others in water and it was thought they didn't much interact. But a tooth found by a University of Tennessee, Knoxville, researcher in the thigh of one of these ancient animals is challenging this belief.
Stephanie Drumheller, an earth and planetary sciences lecturer, and her Virginia Tech colleagues Michelle Stocker and Sterling Nesbitt examined 220-million-year-old bite marks in the thigh bones of an old reptile and found evidence ...
A molecular mechanism involved in cellular proliferation characterized
2014-09-29
Researchers from Guillermo Montoya's team at the Spanish National Cancer Research Centre (CNIO), in collaboration with Isabelle Vernos' Group from the Centre for Genomic Regulation (CRG), have uncovered the molecular interaction between TACC3 and chTOG, key proteins in forming the internal cellular framework that enables and sustains cell division. Published today in Nature Communications, the observations may help to optimise current oncological therapies specifically designed to fight against this framework, named by the scientific community as microtubules.
KEY MOLECULES ...
New method to motivate students to reduce energy consumption
2014-09-29
The research found that a combination of a real-time feedback system together with a human energy delegate in eight halls of residence resulted in a reduction of 37% in energy consumption when compared to normal consumption. The savings were 1360.49 kWh, which is equivalent to a reduction of 713.71 kg of CO2 over four weeks.
In contrast, another eight halls, exposed only to the real-time feedback and a weekly email alert, resulted in saw a 3.5% reduction in energy consumption.
Student's energy-use behaviour is complex as they cannot easily identify how much electricity ...
Dolphins are attracted to magnets
2014-09-29
Dolphins are indeed sensitive to magnetic stimuli, as they behave differently when swimming near magnetized objects. So says Dorothee Kremers and her colleagues at Ethos unit of the Université de Rennes in France, in a study in Springer's journal Naturwissenschaften – The Science of Nature. Their research, conducted in the delphinarium of Planète Sauvage in France, provides experimental behavioral proof that these marine animals are magnetoreceptive.
Magnetoreception implies the ability to perceive a magnetic field. It is supposed to play an important role in how some ...
Human trafficking, an invisible problem
2014-09-29
This news release is available in Spanish. This study compares the existing legislation on this subject in European countries and analyzes both the level of protection afforded to the victims and the measures taken to avoid this crime; in addition, it proposes of code of best practices that favors the enactment of new European guidelines aimed at ending this activity. Specifically, it shows that one of the first obstacles to change is that the magnitude of the problem is not known, points out one of the authors of the report, Begoña Marugán Pintos, of the department ...
Evolutionary biology: It's not just for textbooks anymore
2014-09-29
Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences.
For the first time, an international team of nine scientists has reviewed progress in addressing a broad set of challenges in agriculture, medicine and environmental management using approaches that consider evolutionary histories and the likelihood of rapid adaptation to human activities.
The ...
IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
2014-09-29
Patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy, a phase III trial presented at the ESMO 2014 Congress has shown.
The IMPRESS trial is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer that carried mutations in the EGFR cell surface receptor.
Gefitinib is a type of drug known as a tyrosine kinase ...
Pertuzumab adds 16 months survival benefit to trastuzumab and chemo treatment for HER2-positive breast cancer
2014-09-29
Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy compared to those treated with trastuzumab and chemotherapy alone, updated results from the CLEOPATRA study reveal.
CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive metastatic breast cancer has historically ...